Last reviewed · How we verify
Hydroxychloroquine + lopinavir/ritonavir
This combination uses hydroxychloroquine to modulate immune response and autophagy while lopinavir/ritonavir inhibits viral protease to reduce viral replication.
This combination uses hydroxychloroquine to modulate immune response and autophagy while lopinavir/ritonavir inhibits viral protease to reduce viral replication. Used for COVID-19 (investigational, Phase 3).
At a glance
| Generic name | Hydroxychloroquine + lopinavir/ritonavir |
|---|---|
| Sponsor | UMC Utrecht |
| Drug class | Combination antiviral and immunomodulator |
| Target | Viral protease (lopinavir/ritonavir); endosomal pH and autophagy pathways (hydroxychloroquine) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 3 |
Mechanism of action
Hydroxychloroquine is an antimalarial agent that increases endosomal pH and interferes with viral entry and immune signaling pathways. Lopinavir/ritonavir is a protease inhibitor combination that blocks HIV and coronavirus protease enzymes, preventing viral polyprotein processing and replication. Together, they were investigated for synergistic antiviral and immunomodulatory effects, particularly in viral infections.
Approved indications
- COVID-19 (investigational, Phase 3)
Common side effects
- Gastrointestinal disturbance (nausea, diarrhea)
- Headache
- Retinopathy (hydroxychloroquine)
- QT prolongation
- Hepatotoxicity
Key clinical trials
- Trial of Treatments for COVID-19 in Hospitalized Adults (PHASE3)
- Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19 (PHASE1, PHASE2)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- A Systems Approach to Predict the Outcome of SARS-CoV-2 in the Population of a City; COVID-19
- Randomised Evaluation of COVID-19 Therapy (PHASE3)
- Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers (PHASE3)
- Treatment for COVID-19 in High-Risk Adult Outpatients (PHASE2, PHASE3)
- COVID-19 Study at the Russian Clinical and Research Center of Gerontology of the Pirogov RNRMU
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hydroxychloroquine + lopinavir/ritonavir CI brief — competitive landscape report
- Hydroxychloroquine + lopinavir/ritonavir updates RSS · CI watch RSS
- UMC Utrecht portfolio CI